Prostacyclin: Difference between revisions
CSV import |
CSV import Tags: mobile edit mobile web edit |
||
| Line 22: | Line 22: | ||
{{stub}} | {{stub}} | ||
<gallery> | |||
File:Prostacyclin.svg|Prostacyclin chemical structure | |||
File:Prostacyclin_spacefill.png|Prostacyclin space-filling model | |||
File:Prostacyclin2.png|Prostacyclin | |||
File:Eicosanoid_synthesis.svg|Eicosanoid synthesis pathway | |||
</gallery> | |||
Latest revision as of 04:36, 18 February 2025
Prostacyclin (also called PGI2) is a prostaglandin member of the eicosanoid family of lipid molecules. It is produced in the walls of blood vessels and serves as an important vasodilator and inhibitor of platelet aggregation.
Production[edit]
Prostacyclin is produced from prostaglandin H2 by the action of the enzyme prostacyclin synthase. It is produced primarily in the endothelium of arterial blood vessels. The production of prostacyclin is one of the main ways the body regulates blood flow and clotting.
Function[edit]
Prostacyclin serves several important functions in the body. It is a potent vasodilator, meaning it helps to widen blood vessels and increase blood flow. It also inhibits platelet aggregation, which is the clumping together of platelets in the blood. This helps to prevent the formation of blood clots. Prostacyclin also has anti-inflammatory effects and can help to protect the heart and blood vessels from damage.
Clinical significance[edit]
Prostacyclin and its analogues are used in the treatment of pulmonary arterial hypertension. They work by dilating the blood vessels in the lungs, which reduces the pressure in these vessels and improves symptoms. Prostacyclin is also being investigated for its potential use in the treatment of other conditions, such as atherosclerosis and cancer.


